Integra Life Sciences/ArthroCare
This article was originally published in The Gray Sheet
Executive Summary
510(k) clearance for ArthroCare's Coblation-based spinal surgery system for use in neurosurgery allows Integra to launch the product immediately in the U.S. under an agreement for marketing in North and South America (1"The Gray Sheet" July 31, 2000, p. 18). ArthroCare received a CE mark for the product in February
You may also be interested in...
TriPath Investment By Roche Boosts Stock 36% In August, Index Jumps 11%
A $40 mil. investment in TriPath Imaging by pharmaceutical and diagnostics giant Roche was the driving force behind a 36.1% jump in TriPath's stock price in August. The issue gained 2-3/16 to close the month at 8-1/4.
TriPath Investment By Roche Boosts Stock 36% In August, Index Jumps 11%
A $40 mil. investment in TriPath Imaging by pharmaceutical and diagnostics giant Roche was the driving force behind a 36.1% jump in TriPath's stock price in August. The issue gained 2-3/16 to close the month at 8-1/4.
Integra Boosts Neurosurgery Business Through Arthrocare Distribution Deal
Integra Lifesciences' decision to market Arthrocare's Coblation surgical system for brain tumor removal procedures is a part of the firm's ongoing strategy to bolster its growing neurology business.